Microplastic Contamination in Commercial Antiglaucoma Eye Drops: Occurrence and Material Characterization


Uzun F., Şentürk Koca Y., Aytan Ü.

17th European Glaucoma Society (EGS) Congress, Brussels, Belçika, 30 Mayıs - 02 Haziran 2026, ss.64, (Özet Bildiri)

  • Yayın Türü: Bildiri / Özet Bildiri
  • Basıldığı Şehir: Brussels
  • Basıldığı Ülke: Belçika
  • Sayfa Sayıları: ss.64
  • Recep Tayyip Erdoğan Üniversitesi Adresli: Evet

Özet

PURPOSE

The purpose of this study was to investigate the presence, abundance, physical characteristics, and polymer composition of microplastics in commercially available antiglaucoma eye drops commonly used for long-term treatment. By analysing seven ophthalmic formulations under controlled laboratory conditions, this study aimed to assess whether eye drops may represent a potential direct source of microplastic exposure to the ocular surface and to highlight the need for improved quality control in pharmaceutical products.

 

METHODS

Seven commercially available antiglaucoma eye drops commonly prescribed for chronic ocular use were included in the study. All samples were processed under controlled laboratory conditions to minimize airborne and procedural contamination. The eye drop solutions were directly filtered through pre-cleaned filters, and procedural blanks were prepared in parallel to monitor possible background contamination. After filtration, the retained particles were visually examined and classified according to their morphological characteristics, including particle type, colour, and size. Suspected microplastic particles were then analysed using Infrared (IR) and Raman spectroscopy for polymer identification. Only particles confirmed as synthetic polymers by spectroscopic analysis were considered as microplastics. Microplastic abundance was calculated for each eye drop formulation and expressed as the number of particles per milliliter (items/mL). The detected particles were further evaluated according to their morphology and polymer composition to assess possible contamination sources related to packaging, manufacturing, or storage conditions.

RESULTS
Microplastics were detected in 4 out of the 7 analysed samples. A total of 16 microplastic particles were identified in the ophthalmic solutions. All detected microplastics were classified as fragment-type particles, while no fibres or films were observed. Five different colours were recorded among the detected microplastics: transparent, white, blue, yellow, and black. The most dominant colour was transparent particles, accounting for 38% of the total, followed by white particles (25%), blue particles (19%), yellow particles (13%), and black particles (6%). Polymer identification performed using Shimadzu AIRsight Infrared/Raman spectroscopy confirmed the presence of two synthetic polymer types: polystyrene (PS) and polyethylene (PE). Polystyrene was the dominant polymer, representing 93.7% of the identified particles, while polyethylene accounted for 6.3%.

 

CONCLUSION

Microplastics were detected in most of the analysed antiglaucoma eye drop samples, indicating that ophthalmic solutions may represent a direct and previously overlooked source of microplastic exposure to the ocular surface. Given that antiglaucoma eye drops are commonly used chronically and applied directly to the eye, the presence of microplastics may raise concerns regarding long-term ocular exposure and potential implications for ocular surface health. These findings highlight the need for improved quality control in pharmaceutical manufacturing, packaging, and storage processes, as well as further toxicological studies to assess the possible risks associated with repeated microplastic exposure through ophthalmic formulations.